Investor profile
Lauxera Capital Partners
See how your deck fits this investor's thesis, stage, and ticket size.
Analyse your fitInvestment thesis
Lauxera Capital Partners is an independent, international growth-equity and growth-buyout firm focused exclusively on Healthtech. The firm invests in commercial-stage companies that have generated significant revenue and reached breakeven or early profitability, targeting businesses in medical devices, digital health, pharma services, life science tools, diagnostics, and healthtech IT and data. Lauxera backs both minority and majority positions with tickets of €20–100 million, partnering with world-class management teams to catalyze inflections in growth through new innovation, commercial investment, business development, and talent enhancement — with particular emphasis on scaling European Healthtech companies into the United States and other global markets. Lauxera Growth II, closed at €520 million in 2026, targets the underserved growth-equity gap in the European healthcare innovation ecosystem, deploying capital across 12–15 companies.
Notable quotes
“We are proud to double down on our investment in OrganOx. What a company and what a growth story! We have intensely supported management during this hyper-growth phase across a number of key initiatives: the recruitment of key new functional leaders, driving change efforts via audit and remuneration committee membership and leading the effort to put this round of financing together.”
“What attracted us to Caresyntax, beyond its visionary co-founders and sharp commercial and R&D teams, was the company's 'win-win-win' formula that addresses patient safety and OR costs while delighting its base of enthusiastic surgeon users. We plan to bring our team's global experience in commercialising new healthcare innovations at the deal-by-deal and at the strategic level to support and enhance Caresyntax's mission to make surgery smarter and safer.”
“The entire team at Lauxera could not be more excited to partner with BioLamina in advancing the stem cell field as it delivers breakthroughs in regenerative medicine and in disease research. BioLamina stands at the fulcrum of inflection points in two attractive end markets, with a strong and dedicated executive team, talented employees, and a convicted investor base.”
Recent investments
| Company | Round | Size | Date |
|---|---|---|---|
| OrganOx | Series F | $142m | 2025-02-24 |
| Acandis | Growth | — | 2025-01-01 |
| Antaros Medical | Growth Buyout | — | 2025-07-16 |
| BioLamina | Growth | $19m | 2023-09-12 |
| Caresyntax | Series C | $100m | — |
| LUMICKS | Growth | — | — |
| Natural Cycles | Growth | — | — |
| Lifen | Growth | — | — |
| Matrix One | Growth | — | — |
| Synovo Group | Growth | — | — |
Frequent co-investors
| VC firm | Deals together |
|---|---|
| BGF | 2 |
| HealthQuest Capital | 1 |
| Sofina | 1 |
| Bure Equity | 1 |
| IPF Partners | 1 |
| Optum Ventures | 1 |
Fit check
Is Lauxera Capital Partners a match for your startup?
Upload your deck and get an instant AI-powered fit analysis — see exactly how your startup aligns with this investor's thesis, stage focus, and ticket size.
Analyse your fit